Diagnosis and management of Graves disease: A global overview

Nature Reviews Endocrinology

Volumn 9, Issue 12, 2013, Pages 724-734

  Bartalena, Luigi ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHYROID AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBIMAZOLE; COLESTYRAMINE; GLUCOCORTICOID; IODIDE; IODINE 131; ISOTOPE; LEVOTHYROXINE; LITHIUM CARBONATE; POTASSIUM PERCHLORATE; PREDNISONE; PROPYLTHIOURACIL; THIAMAZOLE;

ADD ON THERAPY; AGRANULOCYTOSIS; CHEMOPROPHYLAXIS; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG MEGADOSE; ENDOCRINE OPHTHALMOPATHY; GEOGRAPHIC AND GEOLOGICAL PARAMETERS; GRAVES DISEASE; HUMAN; ISOTOPE ANALYSIS; LABORATORY TEST; LOW DRUG DOSE; PRIORITY JOURNAL; RADIOGRAPHY; RADIOISOTOPE DIAGNOSIS; REVIEW; THYROIDECTOMY; THYROTOXICOSIS;

ANTITHYROID AGENTS; GRAVES DISEASE; HUMANS;

EID: 84888206548     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2013.193     Document Type: Review

References (137)

1. Brent, G. A. Clinical practice. Graves' disease. N. Engl. J. Med. 358, 2594-2605 (2008).
2. Filipsson Nystrom, H., Jansson, S. & Berg, G. Incidence rate and clinical features of hyperthyroidism in a long-term iodine sufficient area of Sweden (Gothenburg) 2003-2005. Clin. Endocrinol. (Oxf.) 78, 768-776 (2013).
3. Weetman, A. P. Graves' disease. N. Engl. J. Med. 343, 1236-1248 (2000).
4. Brix, T. H., Kyvik, K. O., Christensen, K. & Hegedüs, L. Evidence for a major role of heredity in Graves' disease: a population-based study of two Danish twin cohorts. J. Clin. Endocrinol. Metab. 86, 930-934 (2001). (Pubitemid 32207518)
5. Brand, O. J. & Gough, S. C. L. Genetics of thyroid autoimmunity and the role of the TSHR. Mol. Cell. Endocrinol. 322, 135-143 (2010).
6. Morshed, S. A., Latif, R. & Davies, T. F. Delineating the autoimmune mechanisms in Graves' disease. Immunol. Res. 54, 191-203 (2012).
7. Prabhakar, B. S., Bahn, R. S. & Smith, T. J. Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocr. Rev. 24, 802-835 (2003). (Pubitemid 38067700)
8. Franklyn, J. A. & Boelaert, K. Thyrotoxicosis. Lancet 379, 1155-1166 (2012).
9. Bartalena, L. & Tanda, M. L. Clinical practice. Graves' ophthalmopathy. N. Engl. J. Med. 360, 994-1001 (2009).
10. Tanda, M. L. et al. Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed Graves' hyperthyroidism seen at a single center. J. Clin. Endocrinol. Metab. 98, 1443-1449 (2013).
11. Piantanida, E., Tanda, M. L., Lai, A., Sassi, L. & Bartalena, L. Prevalence and natural history of Graves' orbitopathy in the XXI century. J. Endocrinol. Invest. 36, 444-449 (2013).
12. Fatourechi, V. Thyroid dermopathy and acropachy. Best Pract. Res. Clin. Endocrinol. Metab. 26, 553-565 (2012).
13. Boelaert, K., Torlinska, B., Holder, R. L. & Frannklyn, J. A. Older subjects with hyperthyroidism present with a paucity of symptoms and signs: a large cross-sectional study. J. Clin. Endocrinol. Metab. 95, 2715-2726 (2010).
14. Bartalena, L., Pinchera, A. & Marcocci, C. Management of Graves' ophthalmopathy: reality and perspectives. Endocr. Rev. 21, 168-199 (2000). (Pubitemid 32275594)
15. Burch, H. B., Burman, K. D. & Cooper, D. S. A 2011 survey of clinical practice patterns in the management of Graves' disease. J. Clin. Endocrinol. Metab. 97, 4549-4558 (2012).
16. Bahn, R. S. et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 21, 593-646 (2011).
17. Yoshimura Noh, J. et al. Evaluation of a new rapid and fully automated electroluminescence immunoassay for thyrotropin receptor autoantibodies. Thyroid 18, 1157-1164 (2008).
18. Schott, M. et al. Clinical value of the first automated TSH receptor autoantibody assay for the diagnosis of Graves' disease (GD): an international multicentre trial. Clin. Endocrinol. (Oxf.) 71, 566-573 (2009).
19. Hermsen, D. et al. Technical evaluation of the first fully automated assay for the detection of TSH receptor autoantibodies. Clin. Chim. Acta 401, 84-89 (2009).
20. Lytton, S. D. et al. A novel thyroid-stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy. J. Clin. Endocrinol. Metab. 95, 2123-2131 (2010).
21. Kamijo, K., Murayama, H., Uzu, T., Togashi, K. & Kahaly, G. J. A novel bioreporter assay for thyrotropin receptor antibodies using a chimeric thyrotropin receptor (mc4) is more useful in differentiation of Graves' disease from painless thyroiditis than conventional thyrotropin-stimulating antibody assay using porcine thyroid cells. Thyroid 20, 851-856 (2010).
22. Ajjan, R. A. & Weetman, A. P. Techniques to quantify TSH receptor antibodies. Nat. Clin. Pract. Endocrinol. Metab. 4, 461-468 (2008).
23. Tozzoli, R., Bagnasco, M., Giavarina, D. & Bizzaro, N. TSH receptor autoantibody immunoassay in patients with Graves' disease: improvement of diagnostic accuracy over different generations of methods. Systematic review and meta-analysis. Autoimmun. Rev. 12, 107-113 (2012).
24. Dasgupta, S. & Savage, M. W. Evaluation of management of Graves' disease in district general hospital: achievement of consensus guidelines. Int. J. Clin. Pract. 59, 1097-1100 (2005).
25. Kahaly, G. J., Bartalena, L. & Hegedüs, L. The American Association/American Association of Clinical Endocrinologists guidelines for hyperthyroidism and other causes of thyrotoxicosis: a European perspective. Thyroid 21, 585-591 (2011).
26. Pearce, E. N., Hennessey, J. V. & McDermott, M. T. New American Thyroid Association and American Association of Clinical Endocrinologists guidelines for thyrotoxicosis and other forms of hyperthyroidism: significant progress for the clinician and a guide to future research. Thyroid 21, 573-576 (2011).
27. Yamashita, S., Amino, N. & Shong, Y. S. The American Thyroid Association and American Association of Clinical Endocrinologists hyperthyroidism and other causes of thyrotoxicosis guidelines: viewpoints from Japan and Korea. Thyroid 21, 577-580 (2011).
28. Solomon, B., Glinoer, D., Lagasse, R. & Wartofsky, L. Current trends in the management of Graves' disease. J. Clin. Endocrinol. Metab. 70, 1518-1524 (1990).
29. Glinoer, D., Hesch, D., Lagasse, R. & Laurberg, P. The management of hyperthyroidism due to Graves' disease in Europe in 1986. Results of an international survey. Acta Endocrinol. Suppl. (Copenh.) 285, 3-23 (1987).
30. Nagayama, Y., Izumi, M. & Nagataki, S. The management of hyperthyroidism due to Graves' disease in Japan in 1988. Endocrinol. Jpn 36, 299-314 (1989). (Pubitemid 20037837)
31. Wartofsky, L. et al. Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States. Thyroid 1, 129-135 (1991).
32. Okosieme, O. E., Chan, D., Price, S. A. & Lazarus, J. H. The utility of radioiodine uptake and thyroid scintigraphy in the diagnosis and management of hyperthyroidism. Clin. Endocrinol. (Oxf.) 72, 122-127 (2010).
33. Franklyn, J. A. What is the role of radioiodine uptake measurement and thyroid scintigraphy in the diagnosis and management of hyperthyroidism? Clin. Endocrinol. (Oxf.) 72, 11-12 (2010).
34. Bogazzi, F. & Vitti, P. Could improved ultrasound and power Doppler replace thyroidal radioiodine uptake to assess thyroid disease? Nat. Clin. Pract. Endocrinol. Metab. 4, 70-71 (2008). (Pubitemid 351156882)
35. Vitti, P. et al. Thyroid blood flow evaluation by color-flow Doppler sonography distinguishes Graves' disease from Hashimoto's thyroiditis. J. Endocrinol. Invest. 18, 857-861 (1995). (Pubitemid 26064023)
36. Cappelli, C. et al. The role of imaging in Graves' disease: a cost-effectiveness analysis. Eur. J. Radiol. 65, 99-103 (2008).
37. Boi, F., Loy, M., Piga, M., Serra, A. & Mariotti, S. The usefulness of conventional and echo colour Doppler sonography in the differential diagnosis of toxic multinodular goitres. Eur. J. Endocrinol. 143, 339-346 (2000).
38. Kurita, S. et al. Measurement of thyroid blood flow area is useful for diagnosing the cause of thyrotoxicosis. Thyroid 15, 1249-1252 (2005). (Pubitemid 41821758)
39. Ota, H. et al. Quantitative measurement of thyroid blood flow for differentiation of painless thyroiditis from Graves' disease. Clin. Endocrinol. (Oxf.) 67, 41-45 (2007). (Pubitemid 46955437)
40. Hari Kumar, K. V. et al. Role of thyroid Doppler in differential diagnosis of thyrotoxicosis. Endocr. Pract. 15, 6-9 (2009).
41. Bogazzi, F. et al. Thyroid vascularity and blood flow are not dependent on serum thyroid hormone levels: studies in vivo by color flow Doppler sonography. Eur. J. Endocrinol. 140, 452-456 (1999). (Pubitemid 29254014)
42. Erdogan, M. F., Anil, C., Cesur, M., Baskal, N. & Erdogan, G. Color flow Doppler sonography for the etiologic diagnosis of hyperthyroidism. Thyroid 17, 223-228 (2007). (Pubitemid 46557370)
43. Bahn, R. S. Emerging pharmacotherapy for treatment of Graves' disease. Expert Rev. Clin. Pharmacol. 5, 605-607 (2012).
44. Abraham, P. & Acharya, S. Current and emerging treatment options for Graves' hyperthyroidism. Ther. Clin. Risk Manag. 6, 29-40 (2010).
45. Weetman, A. P. How antithyroid drugs work in Graves' disease. Clin. Endocrinol. (Oxf.) 37, 317-318 (1992).
46. Cooper, D. S. Antithyroid drugs. N. Engl. J. Med. 352, 905-917 (2005). (Pubitemid 40300299)
47. Bogazzi, F., Tomisti, L., Bartalena, L., Aghini-Lombardi, F. & Martino, E. Amiodarone and the thyroid: a 2012 update. J. Endocrinol. Invest. 35, 340-348 (2012).
48. Karlsson, F. A., Axelsson, O. & Melhus, H. Severe embriopathy and exposure to methimazole in early pregnancy. J. Clin. Endocrinol. Metab. 87, 947-948 (2001).
49. Foulds, N., Walpole, I., Elmslie, F. & Mansour, S. Carbimazole embryopathy: an emerging phenotype. Am. J. Med. Genet. A 132A, 130-135 (2005). (Pubitemid 40093320)
50. Clementi, M. et al. Treatment of hyperthyroidism in pregnancy and birth defects. J. Clin. Endocrinol. Metab. 95, E337-E341 (2010).
51. Emiliano, A. B., Governale, L., Parks, M. & Cooper, D. S. Shifts in propylthiouracil and methimazole prescribing practices: antithyroid drug use in the United States from 1991 to 2008. J. Clin. Endocrinol. Metab. 95, 2227-2233 (2010).
52. Ruiz, J. K. et al. Fulminant hepatic failure associated with propylthiouracil. Ann. Pharmacother. 37, 224-228 (2003). (Pubitemid 36172864)
53. Bahn, R. S. et al. The role of propylthiouracil in the management of Graves' disease in adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid 19, 673-674 (2009).
54. Cooper, D. S. & Rivkees, S. A. Putting propylthiouracil in perspective. J. Clin. Endocrinol. Metab. 94, 1881-1882 (2009).
55. Abraham, P., Avenell, A., McGeoch, S. C., Clark, L. F. & Bevan, J. S. Antithyroid drug regimen for treating Graves' hyperthyroidism. Cochrane Database of Systematic Reviews, Issue 1, Art no.: CD003420. http://dx.doi.org/ 10.1002/14651858.CD003420.pub4.
56. Hashizume, K. et al. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. N. Engl. J. Med. 324, 947-953 (1991).
57. Abraham, P., Avell, A., Park, C. M., Watson, W. A. & Bevan, J. S. A systematic review of drug therapy for Graves' hyperthyroidism. Eur. J. Endocrinol. 153, 489-498 (2005). (Pubitemid 41556274)
58. Weetman, A. P., Pickerill, A. P., Watson, P., Chatterjee, V. K. & Edwards, O. M. Treatment of Graves' disease with the block-replace regimen of antithyroid drugs: the effect of treatment duration and immunogenetic susceptibility on relapse. Q. J. Med. 87, 337-341 (1994). (Pubitemid 24188336)
59. Azizi, F., Atale, L., Hedayati, M., Mehrabi, Y. & Sheikholeslami, F. Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine. Eur. J. Endocrinol. 152, 695-701 (2005). (Pubitemid 40744537)
60. Laurberg, P. Remission of Graves' disease during anti-thyroid drug therapy. Time to reconsider the mechanism? Eur. J. Endocrinol. 155, 783-786 (2006). (Pubitemid 46040614)
61. Mazza, E. et al. Long-term follow-up of patients with hyperthyroidism due to Graves' disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study. J. Endocrinol. Invest. 31, 866-872 (2008).
62. Solomon, B. L., Wartofsky, L. & Burman, K. D. Adjunctive cholestyramine therapy for thyrotoxicosis. Clin. Endocrinol. (Oxf.) 38, 39-43 (1993). (Pubitemid 23030271)
63. Tsai, W. C. et al. The effect of combination therapy with propylthiouracil and cholestyramine in the treatment of Graves' hyperthyroidism. Clin. Endocrinol. (Oxf.) 62, 521-524 (2005).
64. Takata, K. et al. Benefit of short-term iodide supplementation to antithyroid drug treatment of thyrotoxicosis due to Graves' disase. Clin. Endocrinol. (Oxf.) 72, 845-850 (2010).
65. Bartalena, L., Bogazzi, F. & Martino, E. Adverse effects of thyroid hormone preparations and antithyroid drugs. Drug Saf. 15, 53-63 (1996). (Pubitemid 26248757)
66. Takata, K. et al. Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily. Thyroid 19, 559-563 (2009).
67. Vitti, P. et al. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid 7, 369-375 (1997). (Pubitemid 27295133)
68. Allahabadia, A., Daykin, J., Holder, R. L., Sheppard, M. C. & Franklyn, J. A. Age and gender predict the outcome of treatment for Graves' hyperthyroidism. J. Clin. Endocrinol. Metab. 85, 1038-1042 (2000). (Pubitemid 32269346)
69. Nedrebo, B. G. et al. Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves' disease. Eur. J. Endocrinol. 147, 583-589 (2002).
70. Kashiwai, T. et al. Practical treatment with minimum maintenance dose of antithyroid drugs for prediction of remission in Graves' disease. Endocr. J. 50, 45-49 (2003). (Pubitemid 36305846)
71. Rotondi, M. et al. The effects of pregnancy on subsequent relapse from Graves' disease after a successful course of antithyroid drug therapy. J. Clin. Endocrinol. Metab. 93, 3985-3988 (2008).
72. Ross, D. S. Radioiodine therapy for hyperthyroidism. N. Engl. J. Med. 364, 542-550 (2011).
73. Vaidya, B., Williams, G. R., Abraham, P. & Pearce, S. H. S. Radioiodine treatment for benign thyroid disorders: results of a nationwide survey of UK endocrinologists. Clin. Endocrinol. (Oxf.) 68, 814-820 (2008). (Pubitemid 351533433)
74. Sztal-Mazer, S. et al. Evidence for higher success rates and successful treatment earlier in Graves' disease with higher radioactive iodine doses. Thyroid 22, 991-995 (2012).
75. Sisson, J. C. et al. Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I: practice recommendations of the American Thyroid Association. Thyroid 21, 335-346 (2011).
76. Walter, M. A. et al. Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomized controlled trials. BMJ 334, 514 (2007).
77. Alexander, E. K. & Larsen, P. R. High dose of 131I therapy for the treatment of hyperthyroidism caused by Graves' disease. J. Clin. Endocrinol. Metab. 87, 1073-1077 (2002). (Pubitemid 36121068)
78. Bonnema, S. J. et al. Resumption of methimazole after 131I therapy of hyperthyroid diseases: effect on thyroid function and volume evaluated by a randomized clinical trial. Eur. J. Endocrinol. 149, 485-492 (2003). (Pubitemid 38063062)
79. Bogazzi, F. et al. Comparison of radioiodine with radioiodine plus lithium in the treatment of Graves' hyperthyroidism. J. Clin. Endocrinol. Metab. 84, 499-503 (1999). (Pubitemid 29075675)
80. Bogazzi, F. et al. Impact of lithium on efficacy of radioactive iodine therapy for Graves' disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal. J. Clin. Endocrinol. Metab. 95, 201-208 (2010).
81. Martin, N. M. et al. Adjuvant lithium improves the efficacy of radioactive iodine treatment in Graves' and toxic nodular disease. Clin. Endocrinol. (Oxf.) 77, 621-627 (2012).
82. Franklyn, J. A., Maisonneuve, P., Sheppard, M. C., Betteridge, J. & Boyle, P. Mortality after the treatment of hyperthyroidism with radioactive iodine. N. Engl. J. Med. 338, 712-718 (1998). (Pubitemid 28115089)
83. Metso, S. et al. Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism. J. Clin. Endocrinol. Metab. 92, 2190-2196 (2007). (Pubitemid 46997120)
84. Vanderpump, M. Cardiovascular and cancer mortality after radioiodine treatment of hyperthyroidism. J. Clin. Endocrinol. Metab. 92, 2033-2035 (2007). (Pubitemid 46997095)
85. Boelaert, K., Maisonneuve, P., Torlinska, B. & Franklyn, J. A. Comparison of mortality in hyperthyroidism during the periods of treatment with thionamides and after radioiodine. J. Clin. Endocrinol. Metab. 98, 1869-1882 (2013).
86. Holm, L. E. et al. Cancer risk after iodine-131 therapy for hyperthyroidism. J. Natl Cancer Inst. 83, 1072-1077 (1991).
87. Ron, E. et al. Cancer mortality following treatment for adult hyperthyroidism. JAMA 280, 347-355 (1998). (Pubitemid 28503219)
88. Read, C. H. Jr, Tansey, M. J. & Menda, Y. A 36-year retrospective analysis of the efficacy and safety of radioiodine in treating young Graves' patients. J. Clin. Endocrinol. Metab. 89, 4229-4233 (2004). (Pubitemid 39244416)
89. Metso, S. et al. Increased cancer incidence after radioiodine treatment for hyperthyroidism. Cancer 109, 1972-1979 (2007). (Pubitemid 46744190)
90. Franklyn, J. A., Maisonneuve, P., Sheppard, M., Betteridge, J. & Boyle, P. Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study. Lancet 353, 2111-2115 (1999). (Pubitemid 29278480)
91. Rivkees, S. A. & Dinauer, C. An optimal treatment for pediatric Graves' disease is radioiodine. J. Clin. Endocrinol. Metab. 92, 797-800 (2007).
92. Tallstedt, L. et al. Occurrence of ophthalmopathy after treatment for hyperthyroidism. N. Engl. J. Med. 326, 1733-1738 (1992).
93. Bartalena, L. et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N. Engl. J. Med. 338, 73-78 (1998). (Pubitemid 28042269)
94. Träisk, F. et al. Thyroid-associated ophthalmopathy after treatment for hyperthyroidism with antithyroid drugs or iodine-131. J. Clin. Endocrinol. Metab. 94, 3700-3707 (2009).
95. Acharya, S. H. et al. Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: a systematic review. Clin. Endocrinol. (Oxf.) 69, 943-950 (2008).
96. Bartalena, L. et al. Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine treatment for hyperthyroidism. N. Engl. J. Med. 321, 1349-1352 (1989). (Pubitemid 19284190)
97. Lai, A. et al. Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent Graves' orbitopathy: a retrospective cohort study. J. Clin. Endocrinol. Metab. 95, 1333-1337 (2010).
98. Tallstedt, L., Lundell, G., Blomgren, H. & Bring, J. Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment? Eur. J. Endocrinol. 130, 494-497 (1994). (Pubitemid 24165777)
99. Perros, P., Kendall-Taylor, P., Neoh, C., Frewin, S. & Dickinson, J. A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graves' ophthalmopathy. J. Clin. Endocrinol. Metab. 90, 5321-5323 (2005). (Pubitemid 41262294)
100. Bartalena, L. Glucocorticoids for Graves' orbitopathy: how and when. J. Clin. Endocrinol. Metab. 90, 5497-5499 (2005). (Pubitemid 41262322)
101. Bartalena, L. et al. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur. J. Endocrinol. 158, 273-285 (2008). (Pubitemid 351404990)
102. Palit, T. K., Miller, C. C. 3rd & Miltenburg, D. M. The efficacy of thyroidectomy for Graves' disease: a meta-analysis. J. Surg. Res. 90, 161-165 (2000). (Pubitemid 30314455)
103. Annerbo, M., Stålberg, P. & Hellman, P. Management of Graves' disease is improved by total thyroidectomy. World J. Surg. 36, 1943-1946 (2012).
104. Al-Adhami, A., Craig, W. & Krukowski, Z. H. Quality of life after surgery for Graves' disease: comparison of those having surgery intended to preserve thyroid function with those having ablative surgery. Thyroid 22, 494-500 (2012).
105. In, H. et al. Treatment options for Graves disease: a cost-effectiveness analysis. J. Am. Coll. Surg. 209, 170-179 (2009).
106. Genovese, B. M., Noureldine, S. I., Gleeson, E. M., Tufano, R. P. & Kandil, E. What is the best definitive treatment for Graves' disease? A systematic review of the existing literature. Ann. Surg. Oncol. 20, 660-667 (2013).
107. Grodski, S., Stålberg, P., Robinson, B. G. & Delbridge, L. W. Surgery versus radioiodine therapy as definitive management for Graves' disease: the role of patient preference. Thyroid 17, 157-160 (2007). (Pubitemid 46365571)
108. Miccoli, P. et al. Minimally invasive video-assisted thyroidectomy for benign thyroid disease: an evidence-based review. World J. Surg. 32, 1333-1340 (2008).
109. Sasaki, A. et al. Endoscopic thyroidectomy by the breast approach: a single institution's 9-year experience. World J. Surg. 32, 381-385 (2008).
110. Lee, J. & Chung, W. Y. Robotic surgery for thyroid disease. Eur. Thyroid J. 2, 93-101 (2013).
111. Sosa, J. A., Mehta, P. J., Wang, T. S., Boudourakis, L. & Roman, S. A. A population-based study of outcomes from thyroidectomy in aging Americans: at what cost? J. Am. Coll. Surg. 206, 1097-1105 (2008).
112. Erbil, Y. et al. Effect of lugol solution on thyroid gland blood flow microvessel density in the patients with Graves' disease. J. Clin. Endocrinol. Metab. 92, 2182-2189 (2007). (Pubitemid 46997119)
113. Marcocci, C. et al. The course of Graves' ophthalmopathy is not influenced by near total thyroidectomy: a case-control study. Clin. Endocrinol. (Oxf.) 51, 503-508 (1999). (Pubitemid 29513319)
114. Laurberg, P. et al. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur. J. Endocrinol. 158, 69-75 (2008). (Pubitemid 351211042)
115. Barczinsky, M., Konturek, A., Hubalewska-Dydejczyk, A., Golkowski, F. & Nowak, W. Randomized clinical trial of bilateral subtotal thyroidectomy versus total thyroidectomy for Graves' disease with a 5-year follow-up. Br. J. Surg. 99, 515-522 (2012).
116. Jin, J., Sandoval, V., Lawless, M. E., Sehgal, A. R. & McHenry, C. R. Disparity in the management of Graves' disease observed at an urban county hospital: a decade-long experience. Am. J. Surg. 204, 199-202 (2012).
117. Sidibé, E. H. Thyréopathies en Afrique subsaharienne [French]. Cahiers Santé 17, 33-39 (2007).
118. Mithal, A., Shah, A. & Kumar, S. The management of Graves' disease by Indian thyroidologists. Natl Med. J. India 6, 163-166 (1993). (Pubitemid 23257502)
119. Pradeep, V. P. et al. Safety and efficacy of surgical management of hyperthyroidism: 15-year experience from a tertiary care center in a developing country. World J. Surg. 31, 306-312 (2007).
120. Sankar, R., Sekhri, T., Sripathy, G., Walia, R. P. & Jain, S. K. Radioactive iodine therapy in Graves' hyperthyroidism: a prospective study from a tertiary referral centre in north India. J. Assoc. Physicians India 53, 603-606 (2005). (Pubitemid 41280032)
121. Ahmed, M. E., ElWasila, A. A., Sanhouri, M. & Yagi, K. Surgical management of toxic goiter in Khartoum. Trop. Geogr. Med. 45, 124-125 (1993). (Pubitemid 23202115)
122. Akossou, S. Y. et al. Problems in the management of thyrotoxicosis in Black Africa: the Tongolese experience [French]. Ann. Endocrinol. (Paris) 62, 516-520 (2001). (Pubitemid 34056632)
123. Walsh, J. P. Management of Graves' disease in Australia. Aust. NZ J. Med. 30, 559-566 (2000).
124. Ford, H. C., Delahunt, J. W. & Feek, C. M. The management of Graves' disease in New Zealand: results of national survey. NZ Med. J. 104, 251-252 (1991).
125. Bartalena, L. The dilemma of how to manage Graves' hyperthyroidism in patients with associated orbitopathy. J. Clin. Endocrinol. Metab. 96, 592-599 (2011).
126. Prummel, M. F. et al. Amelioration of eye changes of Graves' ophthalmopathy by achieving euthyroidism. Acta Endocrinol. (Copenh.) 121 (Suppl. 2), 185-189 (1989). (Pubitemid 20034843)
127. Prummel, M. F. et al. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy. Arch. Intern. Med. 150, 1098-1101 (1990). (Pubitemid 20155338)
128. Perros, P. et al. A questionnaire survey on the management of Graves' orbitopathy in Europe. Eur. J. Endocrinol. 155, 207-211 (2006). (Pubitemid 44269436)
129. Zang, S., Ponto, K. A., Pitz, S. & Kahaly, G. J. Dose of intravenous steroids and therapy outcome in Graves' orbitopathy. J. Endocrinol. Invest. 34, 876-880 (2011).
130. Bartalena, L. et al. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy. J. Clin. Endocrinol. Metab. 97, 4454-4463 (2012).
131. Tanda, M. L. & Bartalena, L. Efficacy and safety of orbital radiotherapy for Graves' orbitopathy. J. Clin. Endocrinol. Metab. 97, 3857-3865 (2012).
132. Elbers, L., Mourits, M. & Wiersinga, W. Outcome of very long-term treatment with antithyroid drugs in Graves' hyperthyroidism associated with Graves' orbitopathy. Thyroid 21, 279-283 (2011).
133. Laurberg, P., Berman, D. C., Andersen, S. & Bülow Pedersen, I. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy. Thyroid 21, 951-956 (2011).
134. Moleti, M. et al. Effects of thyroidectomy alone or followed by radioiodine ablation of thyroid remnants on the outcome of Graves' ophthalmopathy. Thyroid 13, 653-658 (2003). (Pubitemid 36993561)
135. Menconi, F. et al. Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves' orbitopathy treated with intravenous glucocorticoids. J. Clin. Endocrinol. Metab. 92, 1653-1658 (2007). (Pubitemid 46997167)
136. Leo, M. et al. Outcome of Graves' orbitopathy after total thyroid ablation and glucocorticoid treatment: follow-up of a randomized clinical trial. J. Clin. Endocrinol. Metab. 97, E44-E48 (2012).
137. De Bellis, A. et al. Time course of Graves' ophthalmopathy after total thyroidectomy alone or followed by radioiodine therapy: a 2-year longitudinal study. Endocrine 41, 320-326 (2012).Med. 5, 203ra124 (2013)